RT Journal Article
SR Electronic
T1 Outpatient Oral Chemotherapy with S-1 for Unresectable or Distant Metastatic Head and Neck Cancer
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 3285
OP 3289
VO 33
IS 8
A1 MAYUKA MAEDA
A1 TAKU YAMASHITA
A1 TAKESHI MATSUNOBU
A1 KOJI ARAKI
A1 MASAYUKI TOMIFUJI
A1 AKIHIRO SHIOTANI
YR 2013
UL http://ar.iiarjournals.org/content/33/8/3285.abstract
AB Background: This retrospective study evaluated the efficacy and safety of S-1 chemotherapy for unresectable or distant metastatic head and neck cancer. S-1 is an oral anticancer agent containing a combination of 2 modulators and tegafur, which is a pro-drug of 5-fluorouracil. Patients and Methods: S-1 was orally administered to 27 patients with unresectable and/or distant metastatic head and neck cancer at a dose based on the patient's body surface area in an outpatient setting. S-1 was administered for either 14 or 28 consecutive days followed by a 7- or 14-day rest period, respectively. We investigated the response rate, the cumulative survival rate and the time-to-progression for these patients with adverse events. Results: The response rate was 11.1% (three out of the 27 cases: one case of a complete response and two cases of a partial response). The cumulative survival rate of patients with squamous cell carcinoma (n=18) was 7/18 (38.9%) and 4/18 (22.2%) at 12 and 24 months, respectively, with a median survival time of eight months. Most adverse events were mild (up to grade 2). Conclusion: S-1 therapy is a useful, effective anticancer treatment for unresectable or distant metastatic head and neck cancer, with relatively mild side-effects, and can be administered while maintaining the quality of life of the patient.